Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label extension study of conatumumab
2010-022270-14Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of conatumumab in Nonhematologic neoplasms, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 5 more, sponsored by Amgen. Primary endpoints: Adverse events and Serious adverse events. Started Jan 2011; status: completed.
02
Drugs
conatumumab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2010-022270-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022270-14.